Roche gets a leg up in the anti-TIGIT race with first breakthrough designation for PhII winner tiragolumab
In the race to usher in a next generation of immunotherapies, Roche’s Genentech has emerged from the pack, nabbing the first breakthrough designation for an anti-TIGIT drug.
The pharma giant’s tiragolumab plus Tecentriq landed a spot in the FDA’s expedited review program for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in those with high PD-L1 expression and no EGFR or ALK genomic tumor aberrations, Roche said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.